Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction
Abstract Background A recent phase 2A clinical study of Atractylodes lancea (Thunb.) DC. (AL) in patients with advanced-stage intrahepatic cholangiocarcinoma (iCCA) demonstrated significant reduction of the risk of tumor progression and mortality with a dose ranging from 1,000 to 2,000 mg. The prese...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2024-11-01
|
| Serie: | BMC Complementary Medicine and Therapies |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12906-024-04618-8 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|